Halozyme Therapeutics, Inc. (HALO) shares up after passing $1 billion in revenue for first time, strong guidance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback